Laxatives (A61P1/10)

A   Human necessities(312083)
A61P1/10                     Laxatives(47)
Electrolyte laxative // 2640920
FIELD: pharmacology.SUBSTANCE: invention relates to laxative compositions, which contain: from about 2 to about 37 g of water-soluble sodium salt, water-soluble potassium salt; erythrite, xylose, xylotriose or their equivalents; bisoxatin (or 2,2-bis(4-hydroxyphenyl)-2H-benzo[b][1,4]oxazine-3(4H)-on) or bisoxatin acetate or its equivalent.EFFECT: minimizing side effects.35 cl, 4 ex

Crystals of 6,7-unsaturated-7-carbamoyl morphinane derivative, and method for producing same // 2607084
FIELD: chemistry.SUBSTANCE: invention relates to salts of p-toluenesulphonic acid compound of formula (IA) or hydrate thereof, including crystalline forms thereof. Invention relates to form I of crystals of hydrate of salt of p-toluenesulphonic acid compound of formula (IA), where X-ray diffraction spectrum of powder of crystalline has peaks, corresponding to diffraction angles (2θ): 12.9°±0.2°, 17.6°±0.2°, 22.4°±0.2°, 25.4°±0.2° and 28.7°±0.2°. Invention also relates to form II of crystals of hydrate of salt of p-toluenesulphonic acid compound of formula (IA), where X-ray diffraction spectrum of powder of crystalline has peaks, corresponding to diffraction angles (2θ): 8.8°±0.2°, 17.5°±0.2°, 21.9°±0.2°, 23.7°±0.2° and 26.1°±0.2°. Crystalline forms of salts of p-toluenesulphonic acid compound of formula (IA) and hydrates thereof are intended for preparing a pharmaceutical composition, exhibiting agonistic activity with respect to opioid receptor. Crystalline form of salt of p-toluenesulphonic acid compound of formula (IA) or crystalline forms of hydrate of said salt of p-toluenesulphonic acid is obtained by adding p-toluenesulphonic acid to a compound of formula (IA) and crystallisation of salt of p-toluenesulphonic acid or hydrate thereof in a solvent. Method of producing crystalline form or crystalline form of hydrates of said salt of p-toluenesulphonic acid of formula (IA) can also be performed in following steps: 1) treating with a base compound of formula (IIE), where R1a is hydrogen or protecting hydroxyl group, which can be removed by a base selected from a group, consisting of acetyl, formyl, benzoyl, chloroacetyl, pivaloyl, methyl carbonate, isobutyl carbonate, benzyl carbonate, vinyl carbonate, phenyl carbamate, mesyl and tosyl, 2) adding p-toluenesulphonic acid and 3) crystallisation of salt of p-toluenesulphonic acid in a solvent.EFFECT: technical result is stable form of 6,7-unsaturated-7-carbamoyl morphinane.14 cl, 19 tbl, 26 ex ,
Hypertonic solution and method of colon cleansing in mammals // 2600790
FIELD: medicine.SUBSTANCE: group of inventions refers to medicine and is intended for colon cleansing. Hypertonic solution is described, which contains per liter of water solution from 30 to 350 g of polyethylene glycol, from 3 to 20 g of ascorbic acid component, selected from group, consisting of ascorbic acid, ascorbic acid salt or mixture thereof, alkaline metal sulphate or alkaline-earth metal sulphate, preferably, in amount of 1 to 15 g, and (optionally) one or more electrolytes, selected from sodium chloride, potassium chloride and sodium hydrocarbonate, as well as preferably containing flavoring agents. Composition is effective in cleansing intestine for preparing for endoscopy, particularly colonoscopy. Administration of hypertonic solution for colon cleansing is also described.EFFECT: group of inventions allows effective colon cleansing, compliance of patient's regimen and effective use by outpatients.23 cl, 6 ex, 29 tbl
Syrup of senna leaf aquifolium // 2582982
FIELD: pharmaceutics.SUBSTANCE: invention relates to chemical-pharmaceutical industry, in particular to production of pharmaceutical preparation having laxative action. Acutifoliate senna syrup having laxative action, which is obtained by boiling acutifoliate senna leaves with water purified under certain conditions, then the obtained aqueous extract is mixed with refined sugar, mixture is heated until complete dissolution of sugar, brought to boil twice every time removing formed foam, produced syrup is filtered through gauze.EFFECT: syrup described above possesses pronounced laxative action.1 cl, 2 dwg, 1 ex

Syrup made from joster laxative fruits // 2582276
FIELD: pharmaceutics.SUBSTANCE: invention relates to chemical-pharmaceutical industry, in particular to production of pharmaceutical preparation having laxative action. Syrup from rhineberry fruit having laxative action, which is obtained by decoction from rhineberry fruit under certain conditions, then broth is mixed with refined sugar, mixture is heated until sugar is dissolved, bringing to boiling twice, each time removing resulting foam, obtained syrup is filtered through cheesecloth.EFFECT: syrup described above possesses pronounced laxative action.1 cl, 2 ex, 2 dwg
ethod of treating constipation syndrome in children // 2582227
FIELD: medicine.SUBSTANCE: invention is intended for treating constipations in children. Complex therapy with prescribing of preparation “Motilak” is conducted. “Motilak” is received in 14 hours in a dose of 5-10 mg/day, nonabsorbable antacid “Maalox” in dosage of 2.5-5 ml 3 times a day 10-15 minutes after meals, “Natalcid” suppositories alternated with suppositories with sea buckthorn oil and administered at bedtime through rectum, for period of treatment is prescribed milk-free diet, treatment is carried out for 8 weeks.EFFECT: method allows to improve colon motility that provides higher clinical effectiveness, accelerates therapeutic effect, prolongs remission, normalises emptying of intestine.1 cl, 2 ex

Black adler syrup // 2557929
FIELD: medicine.SUBSTANCE: black adler syrup having laxative action, characterised by the fact that it is produced by preparing black adler tea by boiling the raw material with purified water; the tea is further mixed with refined sugar; the mixture is heated until the sugar is dissolved completely and brought to boil twice with skimming as often as it may be required; the prepared syrup is filtered through gauze in the certain environment.EFFECT: syrup is high in anthracene derivatives and possesses the pronounced laxative action.2 dwg, 1 ex

Substituted aminoindans and analogues thereof to be used in pharmaceutics // 2522586
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to compounds of formula , wherein A means a six-merous aryl radical or a five-merous heteroaryl radical which contains one heteroatom specified in oxygen and sulphur; one or more hydrogen atoms in the above aryl or heteroaryl radicals can be substituted by substituting groups R1 which are independently specified in a group consisting of: F, Cl, Br, I, (C1-C10)-alkyl-, (C1-C10)-alkoxy-, -NR13R14; B means a radical with mono- or condensed bicyclic rings specified in a group consisting of: six-ten-merous aryl radicals, five-ten-merous heteroaryl radicals and nine-fourteen-merous cycloheteroalkylaryl radicals, wherein cycloheteroalkyl links can be saturated or partially unsaturated, while the heterocyclic groups can contain one or more heteroatoms specified in a group consisting of nitrogen, oxygen and sulphur, one or more hydrogen atoms in the radical groups B can be substituted by substituting groups R5 (as specified in the patent claim), L means a covalent bond, X means the group -O-, R2 is absent or means one or more substitutes specified in F and (C1-C4)-alkyl radical; R3 and R4 independently mean (C1-C10)-alkyl, (C3-C14)-cycloalkyl, (C4-C20)-cycloalkylalkyl, (C2-C19)-cycloheteroalkyl, (C3-C19)-cycloheteroalkylalkyl, (C6-C10)-aryl, (C7-C20)-arylalkyl, (C1-C9)-heteroaryl, (C2-C19)-heteroarylalkyl radicals, or R3 and R4 together with nitrogen attached whereto can form a four-ten-merous saturated, unsaturated or partially unsaturated heterocyclic compound which can additionally contain one or more heteroatoms among -O-, -S(O)n-, =N- and -NR8-; other radicals are such as specified in the patient claim. Also, the invention refers to using the compound of formula I for preparing a drug.EFFECT: compounds of formula (I) as Na+/H+ metabolism inhibitors NHE3.22 cl, 27 dwg, 1 tbl, 756 ex
Water-miscible dry composition, unit dose, method for preparing colon cleansing solution, aqueous colon cleansing solution and colon cleansing kit (versions) // 2519562
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to chemical-pharmaceutical industry, and represents a composition containing polyethylene glycol 30 to 150 g, an ascorbic acid ingredient 3 to 20 g specified in ascorbic acid, ascorbic acid salt, or a mixture thereof, alkali or alkali earth sulphate, and at least one electrolyte specified in sodium chloride, potassium chloride, and sodium hydrocarbonate in one litre of an aqueous solution; it additionally contains flavouring agents and is effective in the colon cleansing for preparing for an endoscopy, particularly a colonoscopy. The invention contains a unit dose for preparing the colon cleansing solution, the colon cleansing solution, the method for preparing and using the same, and the kit for preparing and using the colon cleansing solution.EFFECT: composition is safer than the standard colon cleansing compositions of sodium phosphate, and thereby may be used for the patients exposed to an elevated risk of using the composition of sodium phosphate, and is more tolerable than the standard compositions of PEG (polyethylene glycol) leading to a better compliance with the regimen and providing the effective use by outpatients.48 cl, 6 ex, 29 tbl

agnesium oxide granules // 2519222
FIELD: chemistry.SUBSTANCE: invention relates to granules as a laxative, containing particles of magnesium oxide of formula Mg2+ 1-xZn2+ x)O (1) with the average diameter of secondary particles 0.1-25 mcm and apparent specific volume 3-20 ml/g. In formula (1) X represents number from 0 to 0.02, content of magnesium oxide particles constitutes from 80 to 95 wt %. Granules also include mannitol and carmellose and have the average particle diameter 0.2-0.4 mm and bulk density 0.4-0.7 g/ml. Content of particles in granules, which have particle diameter from less than 500 mcm to not less than 355 mcm, constitutes from 30 to 45 wt %, content of particles, which have particle diameter from less than 355 mcm to not less than 180 mcm constitutes from 40 to 50 wt %, content of particles, which have particle diameter from less than 180 mcm to not less than 150 mcm, constitutes from 10 to 28 wt %.EFFECT: granules of magnesium oxide possess good solubility, attractive taste and outlook and do not leave sense of roughness in the oral cavity.4 cl, 7 tbl, 2 dwg, 7 ex
ethod of treating patients suffering from first stage cholelithiasis // 2519198
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely gastroenterology, and may be used for treating the patients with the first stage cholelithiasis. That is ensured by administering the preparation Mucofalc 1 sachet 3 times a day for 22-24 weeks.EFFECT: method enables extending the range of drug preparations having litholytic action in the first stage cholelithiasis with no side effects.2 tbl, 2 ex
ethod for modifying procedure of intestine preparation for medical intervention using medical preparation fortrans (macrogol 4000 on basis of macromolecular compound polyethylene glycol) // 2509563
FIELD: medicine.SUBSTANCE: invention refers to medicine, particularly to methods for patient's preparation for diagnostic and therapeutic medical interventions requiring a clean intestine. To prepare the intestine for the medical interventions with using Fortrans (Macrogol), a required quantity of sachets per one intake is calculated according to the table, particularly if a body weight is less than 50 kg and the age is under 50 years old - 1 sachet, the age is between 51 to 70 years old - 1-2 sachets, over 71 years old - 1 sachet, a body weight of 51-70 kg and the age under 50 years old - 1-2 sachets, the age of 51-70 years old - 2-3 sachets, over 71 years old - 2 sachets; a body weight more than 71 kg and the age under 50 years old - 2 sachets, 51-70 years old - 3 sachets, over 71 years old - 2 sachets. Besides, the presence of constipations requires +1 sachet; 1 sachet of Fortrans is dissolved in 1 litre of water.EFFECT: using the method enables extending the indications, taking into account and coping the contraindications, reducing and eliminating the side effects, preparing in the more sparing regimen with underlying minimal emotional load.3 tbl, 2 ex

Antacid and laxative tablet // 2501561
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to an antacid and laxative tablet that contains magnesium oxide particles of the diameter of 0.5 to10 mcm as a main ingredient in the amount of 85 to 96 wt %. The claimed tablet contains crystalline cellulose 2-8 wt % as a binding agent, sodium croscarmellose 0.8-2.5 wt % as a disintegrating agent 1, insoluble polyvinyl pyrrolidone 1-3.5 wt % as a disintegrating agent II and a lubricant 0.5-2 wt %. The invention also refers to a method for preparing the above tablet that involves the mixing of the magnesium oxide particles, crystalline cellulose and the lubricant, and the dry granulation of the prepared mixture to produce the magnesium oxide granules, the mixing of crystalline cellulose, insoluble polyvinyl pyrrolidone and the lubricant with the magnesium oxide granules, and the tableting of the produced granules. The invention also refers to using the claimed tablet for antacid and laxative applications.EFFECT: invention provides preparing the tablet that preserves the long-storage properties of fast disintegration, possess high friability and forms fewer impact cracks and splits.15 cl, 15 tbl, 1 dwg, 30 ex

Pharmaceutical combination of opioid and prostaglandin compound // 2488398
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to pharmaceutics and medicine, and concerns a pharmaceutical combination for treating a condition which indicates for using an opioid, containing oxycodone and a prostaglandin compound of formula , a based pharmaceutical composition, a kit for sales and use of the above pharmaceutical combination for preparing the therapeutic agent for treating the condition which indicates for using the opioid.EFFECT: combination shows higher efficacy.21 cl, 1 tbl, 1 ex

Use of ibat inhibitor for treating and preventing constipation // 2482850
FIELD: medicine.SUBSTANCE: what is presented is the use of an ileal bile acid transporter (IBAT) inhibitor representing some benzothiazepine derivatives for preparing a drug for the use in treating and/or preventing constipation in a warm-blooded animal and human. The invention consists in ileal bile acid transportation wherein the bile acids are used as endogenous relaxants.EFFECT: it is shown that the IBAT administration increases a fecal matter amount after the animals kept the low-fibre and high-protein diet or in a model of constipation either caused by morphine hydrochloride, or following typhlectomy.4 cl
Pharmaceutical composition for preparing infusion solutions of antimicrobial preparations, method for preparing it (versions) // 2476206
FIELD: medicine, pharmaceutics.SUBSTANCE: group of inventions refers to pharmaceutical compositions for preparing infusion solutions of antibacterial and antimycotic preparations, and to methods for preparing them. The declared pharmaceutical compositions are presented in the form of powder, contain sodium chloride and dextrose and particles of colloidal silicone dioxide among which a portion of particles of 5 mcm and less makes less than 35%, in certain weight proportions. A method for preparing said pharmaceutical compositions consists in the fact that sodium chloride in the form of powder and dextrose in the form of powder are mixed with powdered colloidal silicone dioxide in certain proportions; the prepared mixture is mechanically treated by impact abrasion to increase a weight portion of fine particles of silicone dioxide of 5 mcm or less to min. 35%.EFFECT: group of inventions provides the intensified therapeutic effectiveness of parenteral forms of the antibacterial and antimycotic preparations.4 cl, 4 tbl, 3 ex

ethod of manufacturing pharmaceutical product, containing citric acid, magnesium oxide, potassium bicarbonate and sodium picosulfate, pharmaceutical compositions, containing thus obtained granules and intermediate compound // 2473332
FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates to method of manufacturing compositions, containing potassium bicarbonate and sodium picosulfate, which includes stage of application by spraying sodium picosulfate solution on potassium bicarbonate and drying of said salts with formation of granules, containing sodium picosulfate layer on potassium bicarbonate core. Invention also relates to composition, suitable for obtaining composition, which possesses laxative action, which contains granules, including sodium picosulfate layer, applied on potassium bicarbonate core. Invention also relates to composition, possessing laxative action, and to method of its obtaining, which contains granules of homogeneous mixture of citric acid, magnesium oxide, potassium bicarbonate and sodium picosulfate, and possibly sodium saccharin and/or orange flavouring agent, with granules containing sodium picosulfate, applied on potassium bicarbonate core.EFFECT: invention is aimed at obtaining composition, which can be used for emptying of bowels before X-ray examination, endoscopy or surgery, which is homogeneous and possesses improved characteristics.34 cl, 2 dwg, 3 ex
edication for intestinal lavage // 2473330
FIELD: medicine.SUBSTANCE: invention relates to pharmacology and medicine, in particular, to gastroenterology, and represents medication for intestinal lavage, which includes sodium chloride, potassium chloride, sodium phosphate disubstituted, citric acid, sodium acetate, magnesium sulphate and boiled water, characterised by the fact that it additionally contains sorbite, with medication components being in specified ratio.EFFECT: invention ensures achievement of comfortable, predicted complete emptying of intestine, which does not cause unpleasant sensations and impairment of electrolytic composition of blood and tissues.3 ex
Pharmaceutical composition for intestine cleansing // 2472527
FIELD: medicine, pharmaceutics.SUBSTANCE: present invention refers to medicine and describes a pharmaceutical composition containing docusate, an osmotic laxative and benzoate wherein the composition is presented in the form of a solution. What is also described is a disposable packing containing a dose of the pharmaceutical composition, and the use of benzoate for improving stability of the pharmaceutical composition containing docusate, the osmotic laxative and benzoate wherein the composition is presented in the form of a solution.EFFECT: invention provides excellent stability of the composition.15 cl, 3 ex
Treatment-and-preventive agent for relieving constipation // 2456994
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to medicine, namely a treatment-and-preventive agent and may be used in medical institutions as an agent normalising intestinal function, particularly relieving constipation. An aqueous solution containing pectin 7-8%, citric acid 0.8-1%, water - up to 100%.EFFECT: effect of the presented invention consists in relieving constipation by normalising intestinal peristalsis.2 ex

Anthracenedione compounds // 2443415
FIELD: medicine, pharmaceutics.SUBSTANCE: present invention refers to pharmaceutics and medicine, and concerns a composition for inflammatory bowel disease or irritable colon syndrome containing an effective amount of the composition of formula .EFFECT: invention provides higher clinical effectiveness.12 cl, 5 tbl, 5 ex
Compositions of particles containing alginate or alginic acid // 2441648
FIELD: chemistry.SUBSTANCE: invention is referred to the area of pharmacy, namely to the particle compositions for swallowing containing: a. alginate and/or alginic acid; b. bicarbonate and/or carbonate; c. carboxylic acid; and d. agglomerating agent that is a compound such as low-molecular polyol that gives to the particles composition the ability to still flow but not to release significant amount of small particles in the air. The compositions are suitable for direct oral intake by patient and can be used to relieve the esophagus and stomach state.EFFECT: said compositions of particles have excellent flow properties, ability to suppress the dust formation, organoleptic capabilities and stability.21 cl, 6 ex

8-azabicyclo[3,2,1]octane compounds and their application as mu-opioid receptor antagonists // 2423362
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to new compounds of formula (I): , where: R1 is selected from -ORa, -C(O)NRaRb, -NHS(O)2Rc, -C(O)ORa; A means C1-4alkylenyl; R2 means C3-12cycloalkyl or C6-10aryl which is optionally substituted by one -ORa, one or two halogen atoms, one or two C1-3alkyls substituted by two or three halogen atoms; or one, two, three or four C1-3alkyls; G means C1-4alkylenyl; R3 is selected from hydrogen, -C(O)R4, -C(O)NHR5, -S(O)2Rc and -S(O)2NRaRb; R4 means C3-6cycloalkyl or C1-6alkyl, C3-6cycloalkyl is optionally substituted by one -ORa, and C1-6alkyl is optionally substituted by one or two substitutes selected from -ORa, -C(O)ORa, -S(O)2R6, -C(O)NRaRb, -NRaRb, -CN, C3-6cycloalkyl and phenyl; or by one -D-(CH2)j-R7 where D means , j is equal to 1, n is equal to 1 or 2; R6 means C1-3alkyl optionally substituted by R7; R7 means -C(O)ORa; R5 means C1-6alkyl, benzo[1.3]dioxole or -(CH2)q-phenyl; where phenyl is optionally substituted by one or two substitutes selected from halogen, -ORa, C1-3alkiyl and C1-3alkoxy where C1-3alkyl and C1-3alkoxy optionally substituted by 2 or 3 halogen atoms, and q is equal to 0, 1; Ra and Rb independently mean hydrogen or C1-4alkyl; and Rc means C1-3alkyl; provided when R2 means phenyl substituted in position 4, R3 is not -C(O)R4 where R4 means C1-4alkyl substituted by C(O)ORa; to their pharmaceutically acceptable salts. Also, the invention refers to a pharmaceutical composition, to a method of preparing the compound of formula (I), to compounds of formula (II), (III), to application of the compounds on any claim 1-14, to a method of analysing a biological system or a sample containing a mu-opioid receptor, and also to a method of treating a mammal suffering a disease caused by mu-opioid receptor activity.EFFECT: production of the new biologically active compounds exhibiting mu-opioid receptor antagonist activity.26 cl, 204 ex

6,7-unsaturated 7-carbamoyl substituted morphinanderivative // 2403255
FIELD: medicine, pharmaceutics.SUBSTANCE: invention relates to novel compound of general formula (I): , where R1 and R2, each independently, represent hydrogen, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted cycloalkyl, optionally substituted aryl, etc., R3 represents hydrogen, hydroxy, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkinyl, optionally substituted lower alkoxy, etc, R4 represents hydrogen or lower alkyl, R5 represents hydrogen, lower alkyl, cycloalkyl-lower alkyl or lower alkenyl, or its pharmaceutically acceptable salt or solvate.EFFECT: obtaining pharmaceutical composition for treatment and/or prevention of nausea, vomiting and/or constipation.13 cl, 68 tbl, 4 ex
Laxative solid dosage form and method for preparing thereof (versions) // 2401106
FIELD: medicine.SUBSTANCE: solid dosage form consists of a core containing, wt %: bisacodyl - 1.5-12; potato starch - 0.5-10; pregelatinised starch - 2-15; croscarmellose sodium - 0.5-4; colloidal silicon dioxide - 0.2-5; stearic acid and/or its salts - 0.3-1.07; lactose - the rest; and a coating containing, wt %: polyethylene glycol - 0.05-0.2; staining agent - 0.05-0.25; titanium dioxide - 5-25; talc - 20-54; triethyl citrate - 1-7; colloidal silicon dioxide 0.5-2; sodium hydrocarbonate - 0.5-2; sodium lauryl sulphate - 0.1-1 and copolymer of methacrylic acid and ethyl acrylate - the rest.EFFECT: invention ensures good strength and disintegration of a tablet in the neutral or alkalescent intestinal environment.8 cl, 4 tbl

Gastrointestinal stimulator // 2395300
FIELD: medicine.SUBSTANCE: invention refers to medicine and pharmaceutics and concerns an agent gastrointestinal stimulation, specifically for prevention or treatment of functional gastric distresses, appetite regulation etc., containing TIR agonist representing cyclamate or amide derivative of formula as an active agent, a based pharmaceutical composition or a foodstuff and a method for gastrointestinal stimulation.EFFECT: present invention provides improved life quality of the patients.27 cl, 7 dwg, 3 tbl, 6 ex

Prostaglandin derivatives for treating gastrointestinal disorders // 2392941
FIELD: medicine.SUBSTANCE: invention refers to medicine, particularly to gastroenterology, and concerns treating gastrointestinal disorders. That is ensured by administration of the effective amount of a halogenated prostaglandin compound and/or its tautomer.EFFECT: method provides effective treatment in patients of any age and sex without involving electrolyte balance even in long-term introduction for 1 to 6 months and more.54 cl, 8 tbl, 14 dwg, 6 ex
Powder/water mixture, cleaning agent (versions), component set for large intestine depletion (versions), polyethylene glycol as large intestine depletion agent (versions) and method of large intestine depletion (versions) // 2353412
FIELD: medicine.SUBSTANCE: present invention refers to medical products, particularly to large depletion mixture containing the following components per litre of aqueous solution: polyethylene glycol 90 to 150; ascorbic acid and/or ascorbic acid salt 5 to 15; alkaline or earth metal sulphate or mixed alkaline or earth metal sulphates 5 to 10; and electrolyte (sodium chloride, potassium chloride and sodium hydrocarbonate). The mixture agents are chosen so that the osmolarity of the aqueous solution reduced to 1 litre is within 300 to 550 mOsmoles/litre. Besides the invention concerns a cleaning agent, a component set for large intestine depletion, to application of polyethylene glycol as a large intestine depletion agent and to method of large intestine depletion.EFFECT: higher mixture safety and tolerance.39 cl, 29 tbl, 6 ex

Ibat antioxidant application for treatment or prevention of coprostasia // 2342928
FIELD: medicine; pharmacology.SUBSTANCE: IBAT antioxidant application (transport of bilious acids in a iliococcygeus gut), chosen of 1,2,5-benzothiadiazines in treatment and-or prevention of coprostasia at warm-blooded animals, such as the person (versions), corresponding method of treatment and a pharmaceutical composition is described.EFFECT: increase in quantity of excrements at the expense of strengthening of impellent function of intestines, increase in quantity of water in its bottom part content, softening of the content and decrease in a stretching of walls of intestine, reduction of feeling of pain.16 cl, 3 tbl
ethod for preparing patients to endoscopic examination of large intestine // 2321411
FIELD: medicine.SUBSTANCE: method involves giving patient to drink 100 ml of lactulose syrup with 250 ml of liquid at the day before examination. 2-3 h later, intestinal lavage is carried out with 10-15% aqueous lactulose solution being prepared as 100 ml of the syrup diluted with water to volume of 1 l, giving 250 ml to drink every 15 min. Next day, intestinal lavage is carried out with 1 l of aqueous polyethylene glycol solution 3-4 h before performing examination.EFFECT: enhanced effectiveness in cleaning large intestine with smaller volume drugs consumed; improved aged patient tolerance to the procedure.
ethod for treating chronic diseases of large intestine accompanied with constipation syndrome in children // 2313373
FIELD: medicine, pediatrics, gastroenterology.SUBSTANCE: it is necessary to carry out complex therapy of the disease in question and ozonotherapy of the lower department of large intestine. Moreover, 2 h before ozonotherapy one should additionally introduce motilac at the dosage of 2.5 mg for 10 kg/d. Ozonotherapy should be carried out with an ozonator "Ultraton-AMP" due to rectal introduction of a gas-discharge cylindrical electrode for the depth of about 4-6 cm. This procedure should be fulfilled daily at power of 3 W. Impact duration should be prolonged from 5 min up to 10 min. The course lasts for 10 d. The innovation in question provides increased circulation of gastro-intestinal tract and enhanced therapeutic impact of motilac and, as a result, rapid interruption of pain syndrome, inflammatory rectal process and the absence of relapses during 6 mo.EFFECT: higher efficiency of therapy.2 ex
ethod for body healing // 2310456
FIELD: medicine, fitotherapy.SUBSTANCE: claimed method includes administering of medicative herb powder for 5 days daily from 11 o'clock with 2 h interval. The first composition contains horsetail sprouts, hawthorn flours or fruits, bluebottle, chicory, cowberry leaves, green tea leaves, elecampane, tutsan, hyssop roots and/or leaves, and/or inflorescence. The second composition contains cranberry leaves, nettle leaves, maize stigma, burdock roots, coltstoof leaves and rootstocks, carrot seeds, blowball leaves and inflorescence. The third composition contains buckthorn, parsley, tansy flowers, goosegrass leaves. The forth composition contains sagebrash, motherwort, camomile, milfoil grass, senna leaves. The fifth composition contains milfoil grass, senna leaves, blueberry leaves, cinnamon rose fruits. Then 50-100 g of oily balsam prepared g of refined vegetable oil and 14 g of power of 5 plant composition is administered. In evening of fifth day mixture from juice of 3 lemons, 5 grapefruits, 2 oranges and garlic head, glass of squash cranberry and parsley is diluted with silica water up to 3 l, filtered and administered during the sixth day in amount of 100 g after 30 min. During 7th and 8th days flax seed tea is administered 9-10 times in amount of 100 g after 30 min.EFFECT: improved method for body healing.8 cl, 5 ex, 1 tbl

Defecation-promoting pharmaceutical composition // 2294762
FIELD: medicine, pharmacology, organic chemistry, pharmacy.SUBSTANCE: invention relates to novel compounds of the formula (I) promoting the defecation. Also, invention relates to a pharmaceutical composition containing these compounds and a method for promoting defecation and a method for treatment or relief of constipation. Proposed compounds possess the enhanced effectiveness.EFFECT: valuable medicinal properties of pharmaceutical composition.14 cl, 11 tbl, 55 ex
Agent, method for its preparing and method for prophylaxis and treatment of small pelvis organs inflammatory disease and rectum disease // 2288735
FIELD: medicine, pharmacy.SUBSTANCE: invention relates to the development of a novel vegetable-base agent that can be used in treatment of inflammatory diseases of small pelvis organs and diseases of rectum. Agent used in prophylaxis and treatment of diseases of small pelvis organs and diseases of rectum comprises long turmeric (Curcuma longa L.) rhizome dried extract standardized by curcumin, anesthetic agent and pharmaceutically acceptable excipients. Agent is made as a suppository and comprises benzocaine as an anesthetic agent and vitepsol and cacao butter as a suppository base. Method for preparing agent used in prophylaxis and treatment of diseases of small pelvis organs and diseases of rectum involves mixing long turmeric dried extract standardized by curcumin with anesthetic agent and a pharmaceutically acceptable excipient. Method for prophylaxis and treatment of diseases of small pelvis organs and diseases of rectum involves using the proposed agent.EFFECT: improved preparing agent, valuable medicinal properties of agent.9 cl, 3 ex

Derivatives of pyrimidine, pharmaceutical composition, inhibition method and using // 2288227
FIELD: organic chemistry, medicine, pharmacy.SUBSTANCE: invention relates to novel derivatives of pyrimidine of the general formula (I) that possess properties of antagonists to adenosine A2-receptors and can be effective in relieve, for example, of defecation. In compound of the general formula (I) each R1 and R2 represents hydrogen atom; R3 represents hydrogen atom, halogen atom, amino-group, cyano-group, alkyl group comprising 1-6 carbon atoms, alkoxy-group comprising 1-6 carbon atoms, alkenyloxy-group comprising 2-6 carbon atoms, phenyl group that can be substituted with halogen atom, pyridyl group, furyl group or thienyl group; R4 represents pyridyl that can be substituted with a substitute chosen from the group comprising: hydrogen atom, halogen atom, amino-group, mono- or dialkylamino-group, aminoalkylamino-group wherein each has in alkyl residue from 1 to 6 carbon atoms, alkyl group comprising from 1 to 6 carbon atoms that can be substituted with halogen atom, hydroxy-group, amino-group, mono- or dialkylamino-group, alkoxycarbonyl wherein each has in alkyl residue from 1 to 6 carbon atoms, alkoxy-group comprising in alkyl group from 1 to 6 carbon atoms substituted with phenyl or pyridyl, hydroxyalkoxy-group comprising in alkyl residue from 1 to 6 carbon atoms, hydroxycarbonyl, alkoxycarbonyl comprising from 1 to 6 carbon atoms in alkyl residue, alkenyl group comprising from 2 to 6 carbon atoms, alkynyl group comprising from 2 to 6 carbon atoms, piperidinyl group that can be substituted with hydroxyl group, or represents group of the formula (IV): R5 represents phenyl that can be substituted with halogen atom, pyridyl group, thienyl or furyl group.EFFECT: valuable biological properties of derivatives.16 cl, 2 tbl, 185 ex
Anthacidal and aperient tablet // 2284189
FIELD: pharmaceutical industry, in particular antacidal and purgative tablet.SUBSTANCE: claimed tablet for peroral administration contains particles of magnesium oxide as active ingredient, wherein 1) magnesium oxide particles containing in tablet, have average secondary size measured by laser IR-scattering of 0.5-10 mum; 2) tablet contains 99 mass % or more of magnesium oxide particles: 3) tablet is not blacked and essentially has no spots formed in pelletization process; and 4) tablet disintegration time is 10 s or less.EFFECT: tablets with high content of magnesium oxide particles and short disintegration time.12 cl, 6 tbl, 5 ex

Purgative agent composition // 2278666
FIELD: organic chemistry, medicine, pharmacy.SUBSTANCE: invention relates to a purgative agent composition comprising bicyclic compound of the formula (1) and a method providing the purgative effect and using compounds of the formula (1). He composition possesses the enhanced effectiveness.EFFECT: valuable medicinal properties of composition.42 cl, 3 tbl, 2 ex
Sphere-shaped medicine x-ray contrast diagnosis system containing barium sulfate and oxymethyl uracil // 2275197
FIELD: pharmaceutical industry, in particular medicine X-ray contrast diagnosis agent.SUBSTANCE: claimed pellet-shaped agent contains oxymethyl uracil, barium sulfate for fluoroscopy and potato starch in ratio of 4:1 or 6:1, wherein corn is coated with 5 % alcohol/acetone acetylphthalylcellulose solution, 10 % low molecular polyethylene solution in hexane and medical adhesive. Agent of present invention provides disintegration ability of active ingredient in intestine for 2, 4, 6 hours.EFFECT: system for intestinal diagnosis with treating action, improved convenience and sanitary effect.5 ex

Dry laxative mixture, purgative agent, preparative form of dry laxative mixture and method for preparing laxative mixture // 2264223
FIELD: medicine, chemical-pharmaceutical industry, pharmacy.SUBSTANCE: invention relates to the development of purgative agents. Invention proposes novel compositions of medicinal agents possessing the purgative effect, pleasant taste and odor and comprising components taken in the optimal ratio and with minimal doses of separate active components in simultaneous enhancing economy in preparing, providing safety and simplifying a process in using the mixture. Purgative mixture comprising mixture of dry component involves senna extract, purging buckthorn extract and licorice roots extract, and/or major plantain extract, and/or rhubarb extract, and colt's foot extract, and/or oat extract, and/or anise fruits extract, and/or fennel extract as a water-soluble finely dispersed powder or water-soluble granules, or water-soluble tablets, and comprises additionally anise oil or dill oil, or flax oil, or thyme oil, or mint oil, or rose oil, granulated sugar or sugar powder or glucose, or lactose, or fructose, or sorbitol, or xylitol, or any other correcting agent, and mixture comprises additionally a bactericidal and/or stabilizing substance as sodium benzoate, nipagin or nepasol, or sorbic acid or any other preserving agent. A purgative agent comprises a powder-like mixture of senna extract, purging buckthorn extract, licorice roots extract, anise oil, sugar powder and sodium benzoate taken in the definite ratio. Compositions possess a mild purgative effect and without adverse effect.EFFECT: improved and valuable medicinal properties of mixture.15 cl, 5 ex
Gel fraction prepared from plantain flea seeds husk // 2261102
FIELD: medicine, phytotherapy, pharmacy.SUBSTANCE: invention relates to the development of agents of vegetable origin used as purgative agents. Invention proposes the purified form of the gel-forming component from plantain flea seeds husk, and a method for preparing the gel-forming fraction from plantain flea seeds husk. Also, invention proposes methods for applying this gel-forming fraction as a purgative agent. Proposed compositions can be made in different medicinal formulations. Compositions show pleasant taste and safety.EFFECT: improved and valuable properties of gel fraction.20 cl, 6 tbl, 7 ex

2-aminopyridine derivatives, pharmaceutical composition containing the same and method for therapy // 2250898
FIELD: organic chemistry, medicine.SUBSTANCE: invention relates to new 2-aminopyridine derivatives of formula I , wherein R1 is cyano, carboxyl or carbamoyl; R2 is hydrogen, hydroxyl, C1-C6-alkoxy or phenyl; R3 and R4 are aromatic hydrocarbon such as phenyl or naphthyl, 5-14-membered 5-14-membered optionally substituted aromatic group, excepted cases, when (1) R1 is cyano, R2 is hydrogen, and R3 and R4 are simultaneously phenyl;(2) R1 is cyano, R2 is hydrogen, R3 is 4-pyridyl, and R4 is 1-pyridyl; (3) R1 is cyano, R2 is 4-methylphenyl, and R3 and R4 are simultaneously phenyl;(4) R1 is cyano, R2, R3 and R4 are simultaneously phenyl, or salts thereof. Derivatives of present invention have adenosine receptor antagonist activity and are useful in medicine for treatment of irritable bowel syndrome, constipation, and defecation stimulation.EFFECT: 2-aminopyridine derivatives as adenosine receptor antagonists useful in medicine.34 cl, 2 tbl, 179 ex
Contact-type purgative preparation, pharmaceutical composition upon its basis and method for preventing and treating constipations and affected biorhythm of defecation // 2245161
FIELD: chemical and pharmaceutical industry.SUBSTANCE: the present innovation deals with creating medicinal preparations of plant origin and could be applied for treating functional constipations and affected biorhythm of defecation. It is suggested to apply either dry aqueous or aqueous-alcoholic extract of horse chestnut seeds of Aesculus species to prepare curative-prophylactic preparation in case of constipation and affected biorhythm of defecation. The suggested preparation should be applied in the form of powder, tablets or suppositories. Pharmaceutical composition for preventing and treating constipation and affected biorhythm of defecation contains an active substance out of medicinal plant and a pharmaceutically acceptable filling agent, moreover, this preparation is designed as suppositories and contains either dry aqueous or aqueous-alcoholic extract of horse chestnut seeds of Aesculus species and suppository hydrophobic foundation at certain content of ingredients. Dry aqueous or aqueous-alcoholic extract contains 1-50% active substance as escin. As foundation it could contain either cacao oil or vitepsol. The method for preventing and treating constipations and affected biorhythm of defecation deals with introducing the suggested pharmaceutical composition into patient's anus 5-15 min before planned act of defecation. Application of "Rectum-activ" preparation provides positive result at treating functional psychogenic constipation: in 5-15 min after introducing a suppository into anus pronounced urgency for defecation. In case of course therapy for 4 wk one should observe restoration of natural urgency for intestinal evacuation. Moreover, purgative preparation causes no unfavorable pain feelings.EFFECT: higher efficiency.10 cl, 6 ex

The method of obtaining biologically active substances from kelp for medical purposes // 2194525
The invention relates to pharmaceutical industry
 
2550820.
Up!